PRTA Stock Analysis: Prothena | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 419m USD | 12M Return: -18.2% | IE00B91XRN20 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.79M
Qual. Beats: 0
Rev. Trend: -49.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Prothena Corporation plc (NASDAQ: PRTA) is a late-stage clinical biotechnology company headquartered in Dublin, Ireland, focused on discovering and developing therapies for diseases driven by protein dysregulation. Like many clinical-stage biotech firms, it operates without approved commercial products, relying instead on capital markets and partnership revenue to fund its research and development activities.
The companys pipeline is centered on neurodegenerative and amyloid-related diseases. Its most advanced assets include Prasinezumab, an anti-α-synuclein monoclonal antibody in Phase 3 development for Parkinsons disease and other synucleinopathies, and Coramitug, an antibody in Phase 3 trials for transthyretin amyloidosis. Earlier-stage programs include BMS-986446 (anti-tau, Phase 2), PRX019 (Phase 1), and PRX123, a dual Aβ-Tau vaccine in preclinical development for Alzheimers disease. Additional discovery and preclinical efforts target TDP-43 for ALS and next-generation anti-Aβ antibodies.
Prothena maintains two key external partnerships that are typical for small-cap biotechs seeking to offset development costs: a license and commercialization agreement with F. Hoffmann-La Roche covering α-synuclein antibodies including prasinezumab, and a master collaboration agreement with Bristol Myers Squibb covering antibodies targeting tau and TDP-43. The company was incorporated in 2012 and trades on NASDAQ as a small-cap stock within the GICS Biotechnology sub-industry.
- Prasinezumab Phase 3 Parkinsons readout key stock catalyst
- Coramitug Phase 3 ATTR amyloidosis trial results pending
- BMS partnership drives tau Alzheimers program milestones
| Net Income: -24.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 42.03 > 1.0 |
| NWC/Revenue: 497.6% < 20% (prev 2.45k%; Δ -1.95k% < -1%) |
| CFO/TA -0.11 > 3% & CFO -31.4m > Net Income -24.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 23.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.6m) vs 12m ago -4.16% < -2% |
| Gross Margin: 92.98% > 18% (prev 69.58%; Δ 23.40% > 0.5%) |
| Asset Turnover: 16.58% > 50% (prev 3.34%; Δ 13.24% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.93 (Total Current Assets 273.9m - Total Current Liabilities 11.4m) / Total Assets 283.5m |
| B: -4.76 (Retained Earnings -1.35b / Total Assets 283.5m) |
| C: -0.08 (EBIT TTM -25.8m / Avg Total Assets 318.1m) |
| D: 18.31 (Book Value of Equity 268.8m / Total Liabilities 14.7m) |
| Altman-Z'' = 9.24 = AAA |
As of November 21, 2026, the stock is trading at USD 8.22 with a total of 861,976 shares traded. Over the past week, the price has changed by +0.74%, over one month by -3.29%, over three months by -8.97% and over the past year by -18.21%.
Current recommended Stop Loss: 7.60 (which is 7.5% or 1.4 ATR below the current price).
Prothena has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold PRTA.
- StrongBuy: 2
- Buy: 2
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 21.4 | 160.3% |
P/E Forward = 33.8983
P/S = 7.9457
P/B = 1.572
P/EG = 0.8
Revenue TTM = 52.7m USD
EBIT TTM = -25.8m USD
EBITDA TTM = -25.0m USD
Long Term Debt = 3.25m USD (estimated: total debt 6.26m - short term 3.01m)
Short Term Debt = 3.01m USD (from shortTermDebt, last quarter)
Debt = 6.26m USD (from shortLongTermDebtTotal, last quarter) (leases 6.26m already included)
Net Debt = -265.1m USD (calculated: Debt 6.26m - CCE 271.4m)
Enterprise Value = 153.9m USD (419.0m + Debt 6.26m - CCE 271.4m)
Interest Coverage Ratio = unknown (Ebit TTM -25.8m / Interest Expense TTM 0.0)
EV/FCF = -4.78x (Enterprise Value 153.9m / FCF TTM -32.2m)
FCF Yield = -20.90% (FCF TTM -32.2m / Enterprise Value 153.9m)
FCF Margin = -61.01% (FCF TTM -32.2m / Revenue TTM 52.7m)
Net Margin = -45.43% (Net Income TTM -24.0m / Revenue TTM 52.7m)
Gross Margin = 92.98% ((Revenue TTM 52.7m - Cost of Revenue TTM 3.70m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.54 (Enterprise Value 153.9m / Total Assets 283.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.26m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -20.4m (EBIT -25.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 23.95 (Total Current Assets 273.9m / Total Current Liabilities 11.4m)
Debt / Equity = 0.02 (Debt 6.26m / totalStockholderEquity, last quarter 268.8m)
Debt / EBITDA = 10.59 (negative EBITDA) (Net Debt -265.1m / EBITDA -25.0m)
Debt / FCF = 8.24 (negative FCF - burning cash) (Net Debt -265.1m / FCF TTM -32.2m)
Total Stockholder Equity = 287.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.53% (Net Income -24.0m / Total Assets 283.5m)
RoE = -8.34% (Net Income TTM -24.0m / Total Stockholder Equity 287.2m)
RoCE = -8.90% (EBIT -25.8m / Capital Employed (Equity 287.2m + L.T.Debt 3.25m))
RoIC = -7.49% (negative operating profit) (NOPAT -20.4m / Invested Capital 272.5m)
WACC = 9.32% (E(419.0m)/V(425.3m) * Re(9.46%) + D(6.26m)/V(425.3m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.34 | Cagr: -2.84%
[DCF] Fair Price = unknown (Cash Flow -32.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.17 | # QB: 0
Revenue Correlation: -49.57 | Revenue CAGR: -45.01% | SUE: -0.40 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.36 | Chg30d=+12.20% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.66 | Chg30d=N/A | Revisions=+40% | GrowthEPS=+116.5% | GrowthRev=+681.8%
EPS next Year (2027-12-31): EPS=-1.24 | Chg30d=+18.42% | Revisions=+25% | GrowthEPS=-289.3% | GrowthRev=-89.6%
[Analyst] Revisions Ratio: +50% (up=3, down=0)